TruScreen Reports 523% Sales Growth for First Half Year
(WorldNews Health)

Cervical cancer screening company, TruScreen Limited (NZAX: TRU) is reporting significant commercial progress for the second quarter of its financial year, with a number of major events driving adoption of the TruScreen technology. CEO, Martin Dillon, said: `Sales of both devices and the disposal Single Use Sensors are tracking well ahead of last year, with ongoing demand from China and other...